Immuneering Corporation (IMRX) vs NervGen Pharma Corp. Common stock (NGEN)

A side-by-side comparison of Immuneering Corporation and NervGen Pharma Corp. Common stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Immuneering Corporation logo
IMRX
Immuneering Corporation
$139M
$3.83HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
NervGen Pharma Corp. Common stock logo
NGEN
NervGen Pharma Corp. Common stock
$144M
$1.75HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — IMRX vs NGEN

growth of $100 · dividends reinvested · last 1y
IMRX -34.4% (-34.4%/yr)NGEN -57.6% (-57.6%/yr)IMRX compounded faster over this window
406080100120140Start $1002026$66$42
IMRX NGEN

IMRX vs NGEN: by the numbers

  • •NGEN is the larger company ($144M vs $139M market cap).

Metrics side by side

Valuation

MetricIMRXNGEN
P/B ratio0.7311.81

Profitability

MetricIMRXNGEN
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE-30.03%-397.38%
ROIC-32.73%-223.90%

Growth (annualized)

MetricIMRXNGEN
Total return CAGR (5Y)-32.77%N/A

Go deeper

Full IMRX analysisFull NGEN analysisInteractive comparison tool

Dig into the metrics

Immuneering ROENervGen Pharma Corp. Common stock ROEImmuneering operating marginNervGen Pharma Corp. Common stock operating marginImmuneering revenue growthNervGen Pharma Corp. Common stock revenue growthImmuneering free cash flowNervGen Pharma Corp. Common stock free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.